hotspot -WSS

hotspot

author：knowledge 2025-08-12 08:30:13 - browse：21212

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira, which is now facing competition from cheaper biosimilars.

He will be replaced by Chief Operating Officer Robert Michael, who, like Gonzalez, is a longtime AbbVie executive. Gonzalez, 70, will become executive chairman of the board of directors.

Gonzalez should be a sobering reminder to the drug industry’s critics of how resilient a CEO’s reputation can be. Because while he has been a subject of nearly constant criticism for AbbVie’s handling of Humira and the patents protecting it, investors are likely to remember him fondly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： ASCO eve: Let’s set the table for this year's meeting

knowledge

WSS

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Eyeing GLP

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

CEOs share strategies for surviving biotech slump

Hospital price transparency does save money, advocate argues

Reports of telehealth's death have been greatly exaggerated

knowledge

hotspot

knowledge

Medical records are filled with copy

Addressing health care workers' trauma can help fight burnout

Novavax promises a turnaround & Lilly roils the obesity market

Lawmakers consider Medicare pay reforms for doctors

Heart attack and stroke risk calculators need revising

FDA gives detailed accounting of AI

23andMe had bad news about my health. I wish a person had delivered it

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Liver decline slowed by off

focus

FDA struggles to regulate food additives, sometimes for decades

Beam Therapeutics to lay off 20% of its staff, re

The EU Joint Clinical Assessment needs to live up to its promise

FDA warns J&J's Abiomed: We will regulate your software

Beam Therapeutics to lay off 20% of its staff, re

Lawmakers consider Medicare pay reforms for doctors

knowledge

focus

knowledge

entertainment